BPC November 24 update

KURA Phase 1b trial on hold; Ocuphire OCUP Analyst coverage initiated

Pre-Market Updates

Kura Oncology, Inc. (NASDAQ: KURA) placed the KOMET-001 Phase 1b study of KO-539 to treat relapsed or refractory acute myeloid leukemia (AML) on partial clinical hold due to a grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome.

Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase 40,000,000 shares at $1.25 per share. The gross proceeds are expected to be $50 million.

HC Wainwright & Co. initiated coverage on Ocuphire Pharma (NASDAQ: OCUP) with a Buy rating and a price target of $26.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) announced that the FDA denied Breakthrough Therapy Designation (BTD) for aviptadil. The FDA already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced that Pfizer provided an update on the Phase 2b study of vupanorsen to treat cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study met its primary endpoint.

Oppenheimer upgraded Synlogic (NASDAQ: SYBX) shares from Perform to Outperform.

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the U.S. Patent and Trademark Office issued a patent term extension certificate, extending the patent regarding the composition of matter claims for its breast cancer drug Nerlynx by five years.

Pre-Market Advancers

CompanyPriceChange
PTN
Palatin Technologies Inc.
$0.79+0.2324  +41.68%
STSA
Satsuma Pharmaceuticals Inc.
$5.96+0.71  +13.52%
BYSI
BeyondSpring Inc.
$16.25+1.9  +13.24%
ACHL
Achilles Therapeutics plc
$5.39+0.55  +11.36%
OGEN
Oragenics Inc.
$0.60+0.0488  +8.87%
DRMA
Dermata Therapeutics Inc.
$2.93+0.23  +8.52%
UNCY
Unicycive Therapeutics Inc.
$3.16+0.24  +8.22%
WDNA
WisdomTree BioRevolution Fund
$26.00+1.8493  +7.66%
LOGC
LogicBio Therapeutics Inc.
$3.15+0.21  +7.14%
URGN
UroGen Pharma Ltd.
$13.00+0.86  +7.08%

Pre-Market Decliners

CompanyPriceChange
NAVB
Navidea Biopharmaceuticals Inc.
$1.15-0.15  -11.54%
IKT
Inhibikase Therapeutics Inc.
$1.91-0.15  -7.28%
PSTI
Pluristem Therapeutics Inc.
$2.52-0.17  -6.32%
BPTS
Biophytis SA
$5.40-0.36  -6.25%
APVO
Aptevo Therapeutics Inc.
$12.26-0.81  -6.20%
ANGN
Angion Biomedica Corp.
$3.54-0.2099  -5.60%
PBLA
Panbela Therapeutics Inc.
$1.86-0.11  -5.58%
VLON
Vallon Pharmaceuticals Inc.
$5.05-0.26  -4.90%
RVPH
Reviva Pharmaceuticals Holdings Inc.
$3.60-0.18  -4.76%
CRNX
Crinetics Pharmaceuticals Inc.
$23.25-1.15  -4.71%